Previous 10 | Next 10 |
- Biosimilar candidates referencing Prolia ® and XGEVA ® - Builds on first year success of Amneal’s initial three biosimilar launches - Expands existing biosimilar partnership with mAbxience Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Am...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2023 financial results on Tuesday, November 7, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
2023-09-24 07:37:29 ET Summary Amneal Pharmaceuticals exhibits strong Q2 performance with $599M in revenue and diversification in generics and biosimilars. However, its $2.59B long-term debt overshadows growth, raising concerns over liquidity and future financing options. Inve...
2023-09-06 18:16:56 ET More on Amneal Pharmaceuticals Seeking Alpha’s Quant Rating on Amneal Pharmaceuticals Historical earnings data for Amneal Pharmaceuticals Financial information for Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. 2023 Q2 - Res...
- Key injectable currently on the U.S. FDA shortage list - Received Competitive Generic Therapy approval designation Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application...
- 1 st product approval in China represents Amneal’s entry in second largest pharmaceutical market - Expects international expansion will be another key vector for long-term growth and impact Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the ...
- Key ADHD medicine on the U.S. FDA shortage product list - Represents another high-value product approval for Amneal Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Applicatio...
- Senior members of the U.S. Government Visit One of Amneal’s 12 Manufacturing Sites Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that a delegation of senior members of the U.S. Department of Health and Human ...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2023 Wells Fargo Healthcare Conference on September 7, 2023 in Boston. Mr. Pat...
- IPX203 demonstrated statistically significant improvement in daily “Good On” time compared to optimized IR CD/LD, with fewer daily doses Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that JAMA Neurology has published results from the RISE-PD clinical study ...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...